Status:
RECRUITING
Head and Neck Advanced Research for Multi-Omics and Optimized Immunotherapy
Lead Sponsor:
Samsung Medical Center
Conditions:
Head and Neck Cancer
Eligibility:
All Genders
20+ years
Brief Summary
Head and neck squamous cell carcinoma is a heterogeneous cancer with varying prognoses depending on anatomical location and characteristics, and advanced cancers have a poor prognosis. This study aime...
Detailed Description
1\. Background 1.1 Research Background Immune checkpoint inhibitors (ICIs) have emerged as a new class of anticancer therapy following cytotoxic chemotherapy and targeted therapy. They have demonstrat...
Eligibility Criteria
Inclusion
- Histologically confirmed recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
- Received first-line combination therapy with immune checkpoint inhibitor and cytotoxic chemotherapy
- Availability of tumor tissue samples at Samsung Medical Center
- p16 and PD-L1 expression status evaluable within the institution
- Age ≥ 20 years
- Ability to understand the study purpose and provide written informed consent
Exclusion
- Not meeting the inclusion criteria
- Considered ineligible for enrollment at the discretion of the investigator
Key Trial Info
Start Date :
July 8 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07211139
Start Date
July 8 2025
End Date
December 31 2027
Last Update
October 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, Seoul, South Korea, 06351